who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Timmeko Moore Love of Greentown Houston, Anshumali Shrivastava of ThirdAI, and Ghazal Qureshi of UpBrainery. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from edtech to climatetech — recently making headlines in Houston innovation.

Timmeko Moore Love, general manager of Greentown Houston

Timmeko Moore Love has been named Greentown Houston's inaugural general manager. Photo courtesy of Greentown

Greentown Houston has named Timmeko Moore Love as Houston general manager and senior vice president of Greentown Labs. She'll lead Greentown Houston’s team and business operations, while growing the location's membership.

Love has 20 years of experience in innovation management, per the news release, and was the first Black woman at a Fortune 500 to lead a venture capital program. In that role, which was at The Woodlands-based Entergy Corp., she was named to the 2020 Global Corporate Venturing Powerlist. Love also oversaw corporate ventures at Mayo Clinic and Best Buy Capital.

“Greentown Labs is committed to ensuring founders’ success and is an agent of action in the fight against climate change,” says Love in the release. “I am excited to continue my service to the Greater Houston climate innovation ecosystem through this esteemed platform, and partner internally and externally to evolve and expand our services and programs.” Read more.

Anshumali Shrivastava, co-founder and CEO of ThirdAI

Anshumali Shrivastava also serves as an associate professor of computer science at Rice University. Photo via rice.edu

Anshumali Shrivastava's career has evolved alongside the rise of artificial intelligence. Now, he believes his company represents the future of the industry's widespread implementation.

Shrivastava, who's also a professor at Rice University, founded ThirdAI, pronounced "third eye," in 2021 to democratize artificial intelligence through software innovations. As Shrivastava explains on the Houston Innovators Podcast, AI processes have historically been run on larger, less accessible computing hardware. ThirdAI's tools are able to run on a regular central processing unit, or CPU, rather than the more powerful graphics processing unit, or GPU.

"We focus on the problems that people are facing in the current AI ecosystem," Shrivastava says on the podcast. "Right now, if you are to build some of the large-language models and (linear programming) models, you need a lot of computing power, dedicated engineers to move it, and, even if you are using fully managed services, it's costly and there are a lot of privacy implications because you have to move data around." Read more and stream the episode.

Ghazal Qureshi, CEO of UpBrainery

Ghazal Qureshi's Houston-based startup has advanced to the semifinal round of a prestigious national competition. Photo courtesy of Idea Lab Kids

UpBrainery, an immersive educational technology platform that customizes lessons for students, received $20,000 in seed funding from the U.S. National Science Foundation’s Visionary Interdisciplinary Teams Advancing Learning (VITAL) prize challenge. The $6 million prize challenge is cosponsored by the Bill & Melinda Gates Foundation, Schmidt Futures, and the Walton Family Foundation.

“This incredible achievement reflects our commitment to pushing the boundaries of knowledge and technology,” UpBrainery states in a LinkedIn announcement.

In addition to the seed money, UpBrainery will be partnered with a mentor to help them improve the logistics of their exploratory learning and AI aided platform, with a focus on developing their minimum viable prototype. Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted